Iovance Biotherapeutics, INC 8-K filings

Iovance Biotherapeutics updated its corporate presentation, showcasing advancements in its Tumor Infiltrating Lymphocyte (TIL) therapies, including strong clinical data for Amtagvi and a promising pipeline for various solid tumors.

Iovance Biotherapeutics announced record second-quarter 2026 revenue of $99.3 million, a 66% year-over-year increase, alongside significant clinical and regulatory advancements for its TIL therapies.

Iovance Biotherapeutics received marketing authorization from the Australian Therapeutic Goods Administration for its T cell therapy, Amtagvi, to treat advanced melanoma.

Iovance Biotherapeutics announced robust first quarter 2026 financial results, showcasing significant year-over-year revenue growth and providing optimistic guidance for the remainder of the year.

Iovance Biotherapeutics announced that Board member Wendy Yarno will retire and not seek re-election at the upcoming annual meeting.

Iovance Biotherapeutics announced robust fourth quarter and full year 2025 financial results, driven by Amtagvi demand and significant pipeline advancements.

Iovance Biotherapeutics reaffirms its full-year 2025 revenue guidance for Amtagvi sales, expecting to achieve $250 to $300 million in its first full calendar year.

Iovance Biotherapeutics announced robust third-quarter 2025 financial results, driven by increased Amtagvi demand and significant gross margin improvement, while advancing its oncology pipeline.

Iovance Biotherapeutics provides a corporate update, showcasing strong Amtagvi commercialization, a robust clinical pipeline, and a solid financial outlook.

Iovance Biotherapeutics, Inc. has entered into an amended agreement with Jefferies LLC to sell up to $350.0 million of common stock through an at-the-market offering program.

Iovance Biotherapeutics announced Health Canada's approval of Amtagvi (lifileucel) for advanced melanoma, marking its first international market authorization.

Iovance Biotherapeutics announced robust second-quarter 2025 financial results, driven by Amtagvi sales, alongside a strategic restructuring to extend its cash runway into late 2026.

Iovance Biotherapeutics, a commercial biotechnology company, announced the appointment of Corleen Roche, a seasoned financial executive with over 30 years of industry experience, as its new Chief Financial Officer, effective August 6, 2025.

Iovance Biotherapeutics, Inc. announced the immediate departure of its Chief Financial Officer, Jean-Marc Bellemin, and the appointment of Matthew W. Rosinack as interim Principal Financial and Accounting Officer, effective June 30, 2025.

Iovance Biotherapeutics, Inc. announced that its Chief Financial Officer, Jean-Marc Bellemin, will resign effective July 10, 2025, to pursue other opportunities.

Iovance Biotherapeutics, Inc. announced that all five proposals, including the election of directors and amendments to equity incentive plans, were approved by stockholders at its Annual Meeting held on June 10, 2025.

Iovance Biotherapeutics announces its Q1 2025 financial results, including $49.3 million in total product revenue, and updates its full-year revenue guidance to $250-$300 million.

Iovance Biotherapeutics announces positive financial results for Q4 and full year 2024, driven by strong demand for Amtagvi, and reaffirms its revenue guidance for 2025.

Iovance Biotherapeutics has appointed Dan Kirby as its new Chief Commercial Officer to lead the commercialization of Amtagvi and expansion of Proleukin sales.

Iovance Biotherapeutics is relocating its headquarters within the same building in San Carlos, California, securing a substantial reduction in monthly rent.

Iovance Biotherapeutics updated its corporate presentation, highlighting its commercial launch of Amtagvi, pipeline progress, and financial position.

Iovance Biotherapeutics announced robust third-quarter 2024 financial results, driven by strong demand for Amtagvi, and reaffirmed its full-year revenue guidance.

Iovance Biotherapeutics updated its corporate presentation, highlighting the commercial launch of Amtagvi, pipeline advancements, and manufacturing capabilities.

Iovance Biotherapeutics announced strong second-quarter revenue of $31.1 million, driven by the launch of Amtagvi, and increased its full-year revenue guidance.

Iovance Biotherapeutics has submitted a marketing authorization application to the European Medicines Agency for its lifileucel therapy in advanced melanoma, marking a key step in its global expansion strategy.

Iovance Biotherapeutics held its annual meeting on June 11, 2024, where stockholders elected directors and approved several key proposals, including amendments to equity incentive plans.

Iovance Biotherapeutics updated its corporate presentation, highlighting the commercial launch of Amtagvi, pipeline progress, and manufacturing capabilities.

Iovance Biotherapeutics reported a 65% objective response rate and a 30% complete response rate for lifileucel combined with pembrolizumab in frontline advanced melanoma patients, with nearly all responses ongoing at a median follow-up of 21.7 months.

Iovance Biotherapeutics announced a successful start to the U.S. launch of Amtagvi, with over 100 patients enrolled and significant progress in expanding treatment centers, alongside their first quarter 2024 financial results.

Iovance Biotherapeutics has agreed to a settlement in a stockholder derivative lawsuit, which includes governance changes, cancellation of certain option awards, and payment of legal fees.